Cesalatamig controlled disease in 90% at its chosen dose. Is OncoC4 ready for a pivotal NSCLC test?
Cesalatamig produced a 33% response rate at OncoC4’s selected dose in resistant NSCLC, but the 21-patient cohort leaves pivotal proof ahead.
Pharma & Biotech